期刊文献+

左旋门冬酰胺酶治疗儿童急性淋巴细胞白血病凝血四项的变化及意义

Variation and significance of coagulation parametesr in L-asparaginase treatment for children with acute lymphoblastic leukemia
下载PDF
导出
摘要 目的探讨左旋门冬酰胺酶(L-Asp)治疗儿童急性淋巴细胞白血病(ALL)凝血四项的变化及意义。方法我们对64例应用左旋门冬酰胺酶的急淋患儿治疗前1d、治疗过程中及治疗后2d检测凝血酶时间(TT),活化的部分凝血活酶时间(APTT),血浆凝血酶原时间(PT),血浆纤维蛋白原(FIB)和外周血小板计数(PLT)。结果患儿在使用L-Asp过程中出现凝血四项的异常,主要是对纤维蛋白原的影响较大。结论L-Asp对纤维蛋白原的影响较大,适当补充纤维蛋白原,不影响L-Asp继续应用。 [Objective] To discuss variation and significance of coagulation parameters in L-asparaginasc (L- Asp) treating children with acute lymphoblastic leukemia(ALL). [Method] We measured thrombin time (TT), activated partial thromboplastin time (APTT), prothrombin time (PT), blood plasma fibrinogen (FIB) and circular platelet count (PLT) in 64 patients with ALL using the L-ASP at 1 day before treatmen4 during the treatment, and at 2 days after the treatment. [Results] Children appeared abnormal coagulation parameters in using the L-ASP, which mainly influences on the fibrinogen, [Conclusion] The L-ASP mainly influences to the fibrinogen, by suitably supplementing the fibrinogen, L-ASP would be continue to apply.
作者 韦润红
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2006年第19期2960-2962,共3页 China Journal of Modern Medicine
关键词 左旋门冬酰胺酶 儿童 急性淋巴细胞白血病 凝血四项 L-asparaginase children acute lymphoblastic leukemia coagulation parameter
  • 相关文献

参考文献7

二级参考文献24

  • 1王清和.血浆蛋白制品的临床应用(续二)[J].中国输血杂志,1995,8(1):52-55. 被引量:2
  • 2MUELLER MM, BOMKE B, SERFRIED E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases Throm Res, 2002,31;107 suppl1:s9-17.
  • 3DREWS RE. Critical issues in hematology anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically in patients[J]. Clin Chest Med, 2003, 24(4): 607-622.
  • 4BICK RL. Disseminated intravascular coagulation:a revieco of etiology, pathophysiology, diagnosis and managenent: guidelines for care[J]. Clin Appl Thromb hemost, 2002, 8(1): 1-31.
  • 5BAKHSHI S, ARYA LS. Diagnosis and treatment of disseminated intravascular coagulation[J]. Indian Pediatr, 2003, 40(8): 721-730.
  • 6NAKABAYASHI M, ASAMI M, NAKATANI A. Efficacy of antithrombin replacement therapy in severe early-onset preeclampsia[J]. Semin Thromb Hemost, 1999, 25(5): 463-466.
  • 7HARADA N, OKAJIMA K, KUSHIMOTO, et al. Antithrombin Ⅲ reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin[J]. Blood, 1999, 93: 157-164.
  • 8TOTAK G, SCHOBERSBERGER W, SCHLOESSER M, et al.Effects of antithrombinⅢ on tumor necrosis factor-alpha and interlukin-1 beta synthesis in vascular smooth muscular cell [J]. J Interferon Cytokine Res, 2001, 21: 1063-1069.
  • 9UCHIBA M, OKAJIMA K. Antithrombin Ⅲ(ATⅢ) Provents LPS- induced pulmonary vascular injury: Novel biological activity of ATⅢ[J]. Semin Thromb Hemost, 1997, 23(6): 583-590.
  • 10INTHRON D, HOFFAM JN, HARTL WH, et al. Antithrombin Ⅲ Supplementation in severe sepsis:beneficial effects on organ dysfunction[J]. shock, 1997, 8(5): 328-334.

共引文献329

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部